The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Open accessPublished version of a preprint
Abstract
Purpose: Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive with EGFR and KRAS mutations. The prevalence, clinicopathologic characteristics, prognostic implications, and molecular heterogeneity of HER2-mutated lung ADCs are not well established in U.S. patients. Experimental Design: Lung ADC samples (N = 1,478) were first screened for mutations in EGFR (exons 19 and 21) and KRAS (exon 2), and negative cases were then assessed for HER2 mutations (exons 19–20) using a sizing assay and mass spectrometry. Testing for additional recurrent point mutations in EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, and AKT was conducted by mass spectrometry. ALK rearrangements and HER2 amplification were assessed by FISH. Results: We identified 25 cases with HER2 mutations, representing 6% of EGFR/KRAS/ALK-negative specimens. Small insertions in exon 20 accounted for 96% (24/25) of the cases. Compared with insertions in EGFR exon 20, there was less variability, with 83% (20/24) being a 12 bp insertion causing duplication of amino acids YVMA at codon 775. Morphologically, 92% (23/25) were moderately or poorly differentiated ADC. HER2 mutation was not associated with concurrent HER2 amplification in 11 cases tested for both. HER2 mutations were more frequent among never-smokers (P < 0.0001) but there were no associations with sex, race, or stage. Conclusions: HER2 mutations identify a distinct subset of lung ADCs. Given the high prevalence of lung cancer worldwide and the availability of standard and investigational therapies targeting HER2, routine clinical genotyping of lung ADC should include HER2. Clin Cancer Res; 18(18); 4910–8. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Exon 20 of EGFR and HER2 contains two major regions, the α-C helix (residues 762–766 in EGFR and 770–774 in HER2) and the loop following the α-C helix (residues 767–774 in EGFR and 775–783 in HER2)16,19,20,27.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“Together, EGFR and HER2 exon 20 mutations are found in approximately 4% of all patients with NSCLC19.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [19]
In the citing paper
“with the A775_G776insYVMA mutation accounting for most of the mutations seen in NSCLC (17–21).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,039
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
Pinkas‐Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L. N., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 770
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Cited by
Sorted by citations
Items 301–400 of 506
Zheng, S., Chen, R., Zhang, L., Tan, L., Li, L., Long, F., & Wang, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116702 · Cited by 11
Tian, X., Esmaeili, H. A., Minich, D., Seitz, F., Roessner, P. M., Wind, S., Grempler, R., Gan, G., Chan, T. S., Mahmoudi, M., et al. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4641 · Cited by 9
Cai, Q., You, S., Huang, J., Gong, C., Zhang, W., & Zhou, A. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2468070 · Cited by 9
Liu, J., Yu, J., Yu, J., Ren, Q., Cai, Y., Chen, D., & Song, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06589-x · Cited by 10
Lung Cancer in Never-Smokers: Risk Factors, Driver Mutations, and Therapeutic Advances
Chen, P.-M., Huang, Y., & Li, C.-Y. (2026) · Diagnostics · doi:10.3390/diagnostics16020245 · Cited by 9
Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond
Rajan, A., & Schrump, D. S. (2015) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2015.04.002 · Cited by 9
MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer
Pérez-Ramírez, C., Cañadas‐Garre, M., Molina‐Vila, M. Á., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.016 · Cited by 9
Park, C., Hur, J. Y., Choi, C., Kim, T.-O., Cho, H.-J., Shin, H., Lim, J. H., Choi, Y.-D., Kim, Y., & Oh, I. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2018.33.e7 · Cited by 9
Urbán, L., Dóczi, R., Vodicska, B., Tihanyi, D., Horváth, M., Kormos, D., Takács, I., Pápai-Székely, Z., Póka-Farkas, Z., Várkondi, E., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.09.005 · Cited by 10
Yang, Y., Yang, G., Li, W., Hao, X., Zhang, S., Ai, X., Lei, S., Xu, H., & Wang, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15118 · Cited by 8
Jiao, H., Zhao, X., Liu, J., Ma, T., Zhang, Z., Zhang, J., & Wang, J. (2018) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2018.11.004 · Cited by 9
Liu, M., Vathiotis, I. A., Robbins, C. J., Chan, N. N. N., Moutafi, M. K., Burela, S., Xirou, V., Schalper, K. A., Herbst, R. S., Syrigos, K., et al. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100556 · Cited by 8
Milgram, B. C., Borrelli, D. R., Brooijmans, N., Henderson, J. A., Hilbert, B. J., Huff, M. R., Ito, T., Jackson, E. L., Jonsson, P., Ladd, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02377 · Cited by 8
Xing, Y., Cao, Y., Wu, X., Chen, Y., & Wang, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1339806 · Cited by 8
Gao, Y., Zheng, A.-H., Zhu, X., Song, J., & Xue, Q. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182812 · Cited by 8
Yamaoka, T., Tsurutani, J., Sagara, H., & Ohmori, T. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-578 · Cited by 8
Carnio, S., Novello, S., Bironzo, P., & Scagliotti, G. V. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.949245 · Cited by 7
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Fox, A. J., Hiemenz, M., Lieberman, D. B., Sukhadia, S., Li, B., Grubb, J., Candrea, P., Ganapathy, K., Zhao, J., Roth, D. B., et al. (2016) · Journal of Visualized Experiments · doi:10.3791/52758 · Cited by 8
Rúgolo, J. R. M., Fabro, A. T., Ascheri, D., Farhat, C., Ab’Saber, A. M., de Sá, V. K., Nagai, M. A., Takagaki, T. Y., Terra, R. M., Parra, E. R., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.08.026 · Cited by 8
Non-amplification genetic alterations of HER2 gene in non-small cell lung carcinoma
Mehta, A., Nathany, S., Tripathi, R., Sharma, S. K., Saifi, M., & Batra, U. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206730 · Cited by 8
Jia, Z., Xing, J., Li, J., Wang, W., Wang, Y., Song, Y., Yang, X., Xue, J., Ye, J., Li, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-107 · Cited by 7
Qi, H., Xiong, A., Jiang, L., Van, H., Xu, J. Z., Wu, J., Zheng, Q., Minervini, F., Alonso, D. P., Yang, Y., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-860 · Cited by 8
Liu, C., Li, T., Cui, X., Lv, Y., Liu, M., Zhou, X., Yang, F., Dong, Y., Li, R., Zhang, F., et al. (2025) · Cancer Control · doi:10.1177/10732748251347572 · Cited by 7
Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer
Ekyalongo, R., Yamaoka, T., & Tsurutani, J. (2025) · Biomolecules · doi:10.3390/biom15101443 · Cited by 7
Molecular pathology as the driving force for personalized oncology
Oktay, M. H., & Hui, P. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.121 · Cited by 7
Xu, H., Qi, L., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02444-7 · Cited by 7
O’Neill, C. E., Sun, K., Sundararaman, S., Chang, J. C., & Glynn, S. A. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1358850 · Cited by 7
Drug development and evidence for lung cancer targeted therapy in Eastern Asia
Liu, S. M., Jin, Z., Deng, J., Zhong, S.-M., Ahn, M., Horinouchi, H., Li, Y., & Wu, Y.-L. L. C. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101090 · Cited by 8
Yang, G., Liu, R., Li, P., Yang, Y., Wang, Y., Mao, H., & Tang, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01154-2 · Cited by 7
Sun, R.-L., Liao, P.-Y., Liao, Y.-T., Yeh, Y., Chiang, C., Chen, Y.-M., Hsu, K.-H., Tseng, J., Huang, H.-C., Shen, C., et al. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001212 · Cited by 7
Mecanismo de acción y desarrollo preclínico de afatinib
Taín, P. D., González, A. L., & Palomo, A. G. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(16)30257-3 · Cited by 7
The significance of plasma high density lipoprotein cholesterol (hdlc).
Gupta, S., & Rajagopal, G. (2007) · PubMed · Cited by 7
Hoe, H. J., & Solomon, B. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01768 · Cited by 7
In Silico Design of Peptide Inhibitors Targeting HER2 for Lung Cancer Therapy
Alkhatabi, H. A., & Alatyb, H. N. (2024) · Cancers · doi:10.3390/cancers16233979 · Cited by 6
Zhang, Q., Yang, Y., Xie, M., Zhou, Z., Wu, H., Zhai, W., Chen, Y., Chen, K., Zhou, S., Li, H., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108616 · Cited by 6
Lee, S. H., Jeong, H., Kim, D. H., Jang, S. J., Kim, S., Yoon, S., & Lee, K. H. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2023.1177 · Cited by 6
Huang, Y., Zhao, Y., Huang, Y., Yang, Y., Zhang, Y., Hong, S., Zhao, H., Zhao, S., Zhou, T., Chen, G., et al. (2024) · MedComm · doi:10.1002/mco2.536 · Cited by 6
Lin, L., Ge, H., Yan, Z., Wang, G., Wu, X., & Lv, D. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s228726 · Cited by 6
Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials
Palmer, A. C., Plana, D., & Sorger, P. K. (2020) · Cell Systems · doi:10.1016/j.cels.2020.09.003 · Cited by 6
Zhuo, X., Guo, H., Ma, J., Lai, J., Liu, L., Yin, K., Zhao, J., Wang, J., Jiang, F., Xu, W., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04196-7 · Cited by 6
Cai, Y., Liu, H., Chen, X., Yang, J., & Huang, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13645 · Cited by 6
Girard, N. (2013) · Targeted Oncology · doi:10.1007/s11523-012-0246-5 · Cited by 7
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
Toma, A. D., Russo, G. L., Signorelli, D., Pagani, F., Randon, G., Galli, G., Prelaj, A., Ferrara, R., Proto, C., Ganzinelli, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103299 · Cited by 6
Cooper, A. J., & Gainor, J. F. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02550 · Cited by 7
Moorthy, T., Yalamandala, B. N., Huynh, T. M. H., Lien, H., Pan, W.-C., Iao, H. M., Chang, Y., & Hu, S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01935-4 · Cited by 5
Lin, H., Ma, X., Zhu, X., & Zhong, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1630056 · Cited by 6
Liu, S. M., Erazo, T., Jee, J., Arfè, A., Gupta, A., Pike, L., Santini, F. C., Daly, B., Schoenfeld, A. J., Eichholz, J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114257 · Cited by 5
Self-citationMolecular Biomarkers for Lung Adenocarcinoma: A Short Review
Chakravarthi, S., & Karikalan, B. (2020) · Current Cancer Therapy Reviews · doi:10.2174/1573394716666200724164654 · Cited by 5
(2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.101.45 · Cited by 5
Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer
Lim, S. M., Lee, J. B., Oya, Y., Nützinger, J., & Soo, R. A. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00273 · Cited by 6
Qi, Z., Ha, T., Feng, W., Karnoub, M., Pereira, K., Shiga, R., Smit, E. F., Goto, Y., Langen, A. J. D., Goto, K., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2024-0014-oa · Cited by 5
López‐Ríos, F., de Castro, J., Concha, Á., Garrido, P., Gómez‐Román, J., Isla, D., Ramírez, J., Paz-Ares, L. G., Sanz‐Ortega, J., & Felip, E. (2014) · Revista Española de Patología · doi:10.1016/j.patol.2014.10.005 · Cited by 5
Ni, J., Si, X., & Zhang, L. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13889 · Cited by 5
Diao, W., Ding, C.-L., Yuan, B.-Y., Li, Z., Sun, N., & Huang, J. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s328908 · Cited by 5
Sunpaweravong, P., Thongwatchara, P., Chotipanvithayakul, R., Sangkhathat, S., & Thongsuksai, P. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-2705 · Cited by 5
Systemic Therapy for Mutation-Driven NSCLC
Sun, L., Marmarelis, M. E., & Langer, C. J. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.11.011 · Cited by 6
Rous, F. A., Gutta, R., Li, P., Halmos, B., & Gadgeel, S. M. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00873-2 · Cited by 5
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201805187 · Cited by 5
HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?
Bondili, S. K., Nandhana, R., Noronha, V., Pawar, S., Menon, N. S., Shetty, O. A., Chougule, A., Mahajan, A., Kumar, R., Patil, V. M., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_81_21 · Cited by 5
Personalised cancer management: closer, but not here yet
Piccart, M. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt260 · Cited by 5
Ou, S. I. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-201296rep · Cited by 5
Real-world characteristics and outcomes of ERBB2- mutant NSCLC in Latin American patients (CLICaP)
Saldanha, E. F., de Lima, V. C. C., Fares, A. F., Corassa, M. P., Gil-Santana, L., Arrieta, O. G., Soler, J., Chamorro, D. F., Rodrigues, J., Freitas, H., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae347 · Cited by 4
Antibody–drug conjugates in lung cancer: current landscape and future perspectives
Chen, X., & Zhou, C. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001200 · Cited by 4
Dong, Y., Yang, G., Yang, Y., Zhang, S., Wang, Y., & Xu, H. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108062 · Cited by 4
Nogueira, C. D., Frota, S. D. S., Chaves, H. L., de Sousa, J. C., Veloso, G. D. S., Araujo, F. J. D. S., Silva, G. B., Ferreira, S. S., Alves, M. S., Nasser, F., et al. (2025) · Oncotarget · doi:10.18632/oncotarget.28737 · Cited by 4
Fan, F., Zhou, M., Ye, X., Mo, Z., Ma, Y., Luo, L., Liang, X., Liu, H., Weng, Y., Lin, M., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100961 · Cited by 4
König, D., & Rothschild, S. I. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.05.019 · Cited by 4
Cardillo, A. B., Kovar, S., Roper, N., Hicks, D. G., & Velez, M. J. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000719 · Cited by 5
Assessment of HER2 status of carcinomas of various localizations
Vtorushin, S. V., Krakhmal, N. V., Эдуардовна, З. Л., Кузнецова, О. А., Moskvina, L. V., & Франк, Г. А. (2023) · Russian Journal of Archive of Pathology · doi:10.17116/patol20238506131 · Cited by 5
Pan, X., & Zhou, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1397238 · Cited by 4
Metro, G., Giglio, A. D., Ricciuti, B., Siringo, M., Marinelli, D., Gelibter, A. J., Pecci, F., Berardi, R., Cantini, L., Federico, A. D., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-3-9 · Cited by 4
Große, A., & Große, C. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.024 · Cited by 4
Dacomitinib in NSCLC: a positive trial with little clinical impact
Addeo, A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30923-3 · Cited by 4
Zhao, R., Li, J., Guo, L., Xiang, C., Chen, S., Zhao, J., Shao, J., Zhu, L., Ye, M., Qin, G., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01042-3 · Cited by 3
Mao, S., Liu, X., Wang, L., Wang, Y., Yang, S., Jiang, T., Li, X., Wang, Q., Li, X., Wu, F., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.12.022 · Cited by 3
Assessing the risk of second primary lung cancer in women after previous breast cancer
Huang, Y., Lin, J. J., Wisnivesky, J. P., Kong, C. Y., & Sigel, K. M. (2025) · BJC Reports · doi:10.1038/s44276-025-00151-4 · Cited by 3
Sakata, S., Sakamoto, Y., Takaki, A., Ishizuka, S., Saeki, S., & Fujii, K. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9612-17 · Cited by 3
New Targets for Therapy in Lung Cancer
Mansfield, A. S., Dy, G. K., Ahn, M.-J., & Adjei, A. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00048-2 · Cited by 2
Grell, P., Bořilová, S., Bílek, O., & Kišš, I. (2021) · Klinicka onkologie · doi:10.48095/ccko2021s20 · Cited by 3
Targeting Oncogenic Driver Mutations in Lung Cancer
Lee, M. H., Rous, F. A., Borczuk, A., Liu, S. V., Gadgeel, S. M., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009336123 · Cited by 2
Li, P., Li, B., Shi, Y., Zhang, F., Shen, S., & Li, X. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.03.03 · Cited by 3
Treatment of Patients With Non–Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
Marmarelis, M. E., & Langer, C. J. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.010 · Cited by 3
Chang, G., Lam, D. C.-L., Tsai, C., Chen, Y., Shih, J., Aggarwal, S., Wang, S., Kim, S., Kim, Y., Wahid, I., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01869-0 · Cited by 3
Heeke, A. L., Elliott, A., O'Keefe, K., Livasy, C., Symanowski, J. T., Steiner, M. R., Kang, I. M., Hoon, D. S. �., Walker, P., Sledge, G. W., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.23.00719 · Cited by 4
Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls
Russo, G., Scimone, C., Palumbo, L., Roscigno, G., Sarracino, C., Tomaiuolo, I., Pisapia, P., Pepe, F., Rocco, D., Gridelli, C., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104748 · Cited by 2
Ichimata, M., Kagawa, Y., Toshima, A., Igase, M., & Mizuno, T. (2025) · Veterinary and Comparative Oncology · doi:10.1111/vco.70020 · Cited by 2
Wang, H., Sun, W., Wang, C., Yang, X., Chi, K., Liu, X., Huang, X., Zhou, L., & Lin, D. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.11.015 · Cited by 2
Evolving treatment strategies for HER2-altered non–small-cell lung cancer: the rise of TKIs and ADCs
Ballı, S., Başoğlu, T., & Ozdogan, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771869 · Cited by 2
Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer
Kim, J., & Ahn, M. (2026) · Future Oncology · doi:10.1080/14796694.2026.2658641 · Cited by 2
Yin, Y., Song, L., Shi, D., Liu, B., Li, X., Yang, M., Liu, B., Wang, D., & Qin, J. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00325 · Cited by 3
ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China
Li, H., Li, X., Lan, S., Zuo, X., Du, T., Liu, Y., Zhang, C., Zhu, J., & Cheng, Y. (2022) · Tumori Journal · doi:10.1177/03008916221101426 · Cited by 2
Cho, D., Lord, S. J., Simes, R. J., Cooper, W. A., Friedlander, M. L., Bae, S., & Lee, C. K. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221112822 · Cited by 2
Brodeur, M. N., Selenica, P., Ma, W., Moufarrij, S., Dagher, C., Basili, T., Abu‐Rustum, N. R., Aghajanian, C. A., Zhou, Q. C., Iasonos, A. E., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13698 · Cited by 2
Terashima, Y., Park, S., Ikeuchi, H., Hayashi, T., Kojima, S., Ueno, T., Ikegami, M., Kitada, R., Suehara, Y., Tanaka, S., et al. (2025) · Cancer Science · doi:10.1111/cas.70142 · Cited by 2
Section IV: Non–small cell lung cancer and malignant melanoma
Fisher, K. E., Pillai, R. N., Kudchadkar, R. R., & Rossi, M. R. (2014) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2014.08.007 · Cited by 2
Micropapillary Adenocarcinoma of the lung: Recent updates and literature review
Monroig-Bosque, P. D. C., Shehabeldin, A. N., & Ro, J. Y. (2019) · Archives of Pulmonology and Respiratory Care · doi:10.17352/aprc.000035 · Cited by 2
Animal models and in vivo investigations for drug repurposing in lung cancer
Chang, H.-W. K., & Chang, V. H. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00010-5 · Cited by 2
Gong, K., Yang, Y., Huang, H., Kuang, X., & Yang, X. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2375 · Cited by 2
Zhao, H., Yang, H., Yu, X., Feng, H., & Yang, F. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001298 · Cited by 2
Metadata
- Authors
- Arcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Authors' Affiliations: 1Department of Pathology, and 2Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
- National Institutes of Health (US)
- Corresponding author
- Arcila, Maria E.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-09-15
- Volume
- 18
- Issue
- 18
- Pages
- 4910-4918
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3865806
- OpenAlex
- W2107562400
- Cited by
- 505
- References
- 48
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 36 · 2023: 40 · 2022: 39 · 2021: 52 · 2020: 42 · 2019: 30 · 2018: 42 · 2017: 30 · 2016: 23 · 2015: 43 · 2014: 37 · 2013: 31 · 2012: 4
- FWCI
- 29.67
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (P01CA129243, T32CA009207, R25CA020449)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- HER2 mutation, lung adenocarcinoma, tyrosine kinase mutations, exon 20 insertion, never smokers, HER2 amplification, EGFR, KRAS, ALK rearrangement, molecular subtyping, clinicopathological features, molecular heterogeneity
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Risk Factors, Prevalence, Survival Analysis, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Protein Interaction Domains and Motifs, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
